6th WORLD SCIENCE FORUM: 24 – 27 November, 2013 RIO, Brazil
Parallel Thematic Session: 16h00 – 18h00, Tuesday 26th November
Organised by SciCom
- Hotel Windsor Atlantica, Room Buzios B
Leveraging The Nexus Between Health Science, Policy & Business: Insights From The BRICS, USA & Europe
Health is big business. It is also a lynchpin of development-based foreign policy. All nations, large and small, invest in global public goods. Together, we strive to secure the right to the health benefits of science for our most vulnerable populations. This story is well known. Less evaluated are the transformational scientific and commercial significances of cause-related health partnerships. International scientific, economic and philanthropic institutions are engaging with civil societies to enable health on a massive scale. Benefits are far-reaching. Impacts alone on skills development in science, medicine and associated industries are profound. Novel business clusters are promoting partnerships, innovations and capacity-building, while creating health-tech transfers, jobs and growth. Diverse enterprises and regions are benefiting.
World Conference of Science Journalists 2013
SciCom will be leading an ESOF 2014 Copenhagen Delegation to the World Conference of Science Journalists 2013 which will be held in Helsinki, Finland from 23 – 26 June.
The leading theme of the conference is Critical thinking in the public sphere. This applies equally to both journalists and the public. Media content and channels are in rapid flux. Evolution is taking place in the social media. What does this mean for science journalism?
Substance Addictions & Their Brain Reward Systems: Drugs, Alcohol & Nicotine
Click here or scroll down to view event presentation downloads
Convener’s Introduction: Why This Science Matters?
Wouldn't it be wonderful to attribute our compulsion for addictive damaging activities, such as over-drinking, smoking or taking illicit drugs, wholly to our genetic make-up? Then we could blame our parents for everything! We know it is bad for us, but we still do it. Why?
Clinical Trial and Error: Beauty and the Beast
Organised by SciCom
Co-Organised by: Thomas Hartung, Johns Hopkins University
14 – 18 February, 2013, Boston USA
Annual Meeting, American Association for the Advancement of Science (AAAS):
The Beauty and the Benefits of Science
Independent clinical trials are fundamental to improving the results, safety, and cost-effectiveness of health care. Because of costs, the scope of these trials is often limited to new products. Important clinical interventions, surgery, physiotherapy, and rehabilitation are of less interest to commercial sponsors seeking primarily drug and device authorization. Whereas investigator-driven studies now find support in the United States and European Union, they cannot match the resources available for commercial clinical trials. Public and charitable funding typically backs health care–orientated trials independently of manufacturers, but is often much smaller in size. Results matter. When we do get such new evidence, it allows us to look back: how good was the preclinical research to start with? While evidence-based medicine is the health care imperative of the 21st century, it remains difficult to generate the evidence base for pressing public health challenges. This session unites key stages and world authorities in the clinical trials process to explain why and what must change. With expertise on leading animal and human studies to end products, speakers will provide new insights into how clinical trials are conducted. Their common cause will be to argue that greater international cooperation and standards are required. That said, effective communication of clinical and societal benefits must be better coordinated to citizens, patients, health-care professionals, researchers, policy-makers, and society as a whole.
